Timothy Rydell, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 61 Emerald Pl, Rock Hill, NY 12775 Phone: 845-703-6999 Fax: 845-703-6297 |
Dr. Tapti Panda, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 61 Emerald Pl, Rock Hill, NY 12775 Phone: 845-794-6999 Fax: 845-703-6297 |
Dr. Melissa Coll Kubenik, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 61 Emerald Pl, Rock Hill, NY 12775 Phone: 845-794-6999 Fax: 845-703-6297 |
Marie Abougou, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 61 Emerald Pl, Rock Hill, NY 12775 Phone: 845-794-6999 Fax: 845-703-6297 |
News Archive
Researchers have shown that point mutations mis-spellings in a single letter of genetic code that drive the onset and growth of cancer cells can be detected successfully in advanced ovarian cancer using a technique called OncoMap. The finding opens the way for personalised medicine in which every patient could have their tumour screened, specific mutations identified, and the appropriate drug chosen to target the mutation and halt the growth of their cancer.
A new study published online in the Annals of the American Thoracic Society examines if the source of physician payment for a medical opinion influences whether the physician finds that a coal miner has black lung disease. The study is the first to look at this relationship in the workers' compensation process.
New research published today in the Journal of Cell Biology illuminates the mechanical factors that play a critical role in the differentiation and function of fibroblasts, connective tissue cells that play a role in wound healing and scar tissue formation.
CEL-SCI Corporation announced today it has received governmental approval from the Health Authority, Ministry of Health of Ukraine, to begin enrollment of subjects for a Phase III clinical trial of Multikine® in Ukraine. Multikine is the Company's flagship immunotherapy developed as a first-line standard of care in treating head and neck cancer. Ukraine is one of nine countries to participate in this global Phase III trial. The Phase III trial will be run at about 48 clinical centers, of which about 6 centers will be in Ukraine.
› Verified 8 days ago